2月25日 - ** 药物开发商Adial Pharmaceuticals ADIL.O股价上涨68.8%至1.30美元
** ADIL称 (link)，美国FDA同意该公司的计划，即采用一种名为 "体外桥接策略 "的特定方法来支持AD04的开发，以治疗酗酒患者的酒精使用障碍。
** 这种方法包括利用现有数据和实验室测试来证明新版 AD04 与旧版 AD04 具有同等疗效。
** 公司正在为即将于今年开始的后期试验开发这种药物
** 去年 (link)，AD04 显示出与现有疗法一致的安全性和耐受性
** 2024 年 ADIL 下降 42.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.